Methylation Status of Alu and LINE-1 Interspersed Repetitive Sequences in Behcet’s Disease Patients

Table 2

LINE-1 methylation frequency of BD patients and healthy controls. The results represented as the average ± standard deviation.

	%  C	%  CC	%  CC	%  CC	%  CC	%  CC + CC
PBMC control ()	81.76 ± 2.04	81.76 ± 2.04	9.62 ± 3.39	16.42 ± 1.08	5.22 ± 1.07	26.05 ± 3.87
PBMC active ()	81.61 ± 1.63	68.93 ± 2.59	8.29 ± 1.92	17.07 ± 1.39	5.71 ± 0.80	25.37 ± 2.03
PBMC inactive ()	81.15 ± 1.18	68.21 ± 1.57	9.80 ± 1.97	16.07 ± 1.28	5.92 ± 1.59	25.87 ± 2.10
PBMC all patients ()	81.34 ± 1.37	68.51 ± 2.04	9.18 ± 2.06	16.48 ± 1.40	5.83 ± 1.31	25.66 ± 2.05
Neutrophil control ()	81.06 ± 1.94	67.73 ± 2.92	11.01 ± 2.03	15.64 ± 0.55	5.61 ± 1.20	26.65 ± 2.23
Neutrophil active ()	82.07 ± 0.96	69.12 ± 1.39	10.06 ± 1.20	15.86 ± 1.32	4.97 ± 0.61	25.92 ± 0.98
Neutrophil inactive ()	81.35 ± 1.25	67.82 ± 2.04	11.06 ± 2.54	16.01 ± 1.73	5.11 ± 0.89	27.07 ± 1.91
Neutrophil all patients ()	81.65 ± 1.18	68.36 ± 1.89	10.64 ± 2.12	15.95 ± 1.55	5.05 ± 0.78	26.59 ± 1.67